Rosetta Genomics (ROSG) Receives News Sentiment Rating of 0.06

Headlines about Rosetta Genomics (NASDAQ:ROSG) have been trending somewhat positive on Wednesday, Accern reports. Accern ranks the sentiment of media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Rosetta Genomics earned a media sentiment score of 0.06 on Accern’s scale. Accern also gave headlines about the medical research company an impact score of 46.3267177265137 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Shares of Rosetta Genomics (NASDAQ ROSG) opened at $0.70 on Wednesday. Rosetta Genomics has a 52 week low of $0.61 and a 52 week high of $9.72. The company has a quick ratio of 2.10, a current ratio of 2.10 and a debt-to-equity ratio of 0.03.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.chaffeybreeze.com/2017/11/15/rosetta-genomics-rosg-receives-news-sentiment-rating-of-0-06.html.

Rosetta Genomics Company Profile

Rosetta Genomics Ltd. is engaged in developing and commercializing new diagnostic tests based on various genomics markers, including deoxyribonucleic acid (DNA), micro ribonucleic acid (microRNA) and protein biomarkers and using various technologies, including, Quantitative polymerase chain reaction (qPCR), microarrays, Next Generation Sequencing (NGS) and Fluorescence In Situ Hybridization (FISH).

Insider Buying and Selling by Quarter for Rosetta Genomics (NASDAQ:ROSG)

Receive News & Ratings for Rosetta Genomics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rosetta Genomics Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply